Elicera To Advance Next-Gen Cell Therapies Following IPO
Interview With CEO Jamal El-Mosleh
Sweden-based Elicera Therapeutics is developing next-generation oncolytic viruses and “fourth-generation” CAR-T cells. CEO Jamal El-Mosleh sat down with In Vivo ahead of the company’s IPO.
You may also be interested in...
In this installment of our VC Playbook series, In Vivo sits down with Isabelle de Cremoux, CEO of Seventure. The company has been a pioneer investor in the microbiome space, which Cremoux believes has now reached a turning point.
A selection of articles you might have missed from May 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.